Cytokinetics, Incorporated
CYTK
$36.69
-$0.95-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -615.26M | -589.53M | -576.40M | -545.28M | -530.60M |
| Total Depreciation and Amortization | 9.50M | 9.53M | 13.48M | 12.93M | 12.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 151.60M | 148.44M | 119.73M | 102.87M | 100.11M |
| Change in Net Operating Assets | 56.16M | 35.66M | 38.83M | 30.43M | -3.44M |
| Cash from Operations | -398.00M | -395.89M | -404.36M | -399.06M | -421.55M |
| Capital Expenditure | -9.57M | -3.91M | -2.69M | -2.21M | -1.01M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -470.21M | -549.19M | -742.68M | -625.07M | 107.41M |
| Cash from Investing | -479.78M | -553.10M | -745.37M | -627.28M | 106.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.57M | -9.62M | -6.93M | -4.25M | -1.58M |
| Issuance of Common Stock | 644.34M | 759.86M | 922.40M | 920.52M | 302.32M |
| Repurchase of Common Stock | -1.20M | -19.63M | -18.45M | -18.45M | -18.45M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00M | 200.00M | 200.00M | 250.00M | 50.00M |
| Cash from Financing | 831.57M | 930.61M | 1.10B | 1.15B | 332.29M |
| Foreign Exchange rate Adjustments | -88.00K | 209.00K | -103.00K | 23.00K | 7.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -46.30M | -18.17M | -52.80M | 121.50M | 17.14M |